Plain-English translation of NCT06793709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Biliary Tract Cancer research guide →This is a safety study of Tasfygo, a medication designed for people with a specific type of advanced bile duct cancer. Researchers want to carefully monitor how well the medication is tolerated and what side effects people experience when taking it. This study will help doctors understand whether this treatment is safe for patients like you.
Bile duct cancer is serious and often hard to treat, especially when it has spread and stopped responding to standard chemotherapy. This medication targets a specific genetic change in the cancer cells, but doctors need real-world information about how safe and manageable the treatment is for patients who use it.
You likely qualify if…
You likely don't qualify if…
You will take the medication (35 mg tablets) as prescribed by your doctor while researchers monitor your health and safety. The study will track how you respond to treatment and what side effects, if any, you experience. Doctors will likely ask you to come in for visits and may do blood tests or scans to check how you are doing.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Japan
Sponsor
Eisai Co., Ltd.
Enrollment target
~60 participants
Started
July 2025
Primary completion
November 2032
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eisai Inquiry Service
Eisai Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.